Monday, 18 Jun 2018

You are here

Increased Comorbidity Burden in Lupus African Americans

Researchers from Vanderbilt University Medical Center used electronic health records (EHR) to perform a phenome-wide study comparing African American (AA-SLE) and Caucasian (C-SLE) with systemic lupus erythematosus (SLE) and found more comorbidities in AA-SLE, especially renal, cardiovascular, and infectious diseases.

Among 2.8 million EHR de-identified subjects were 270 AA-SLE, 715 C- SLE and and 1425 matched African American controls.

They found that AA-SLE patients had more comorbidities in every organ system compared to C-SLE, including more:

  • hypertension odds ratio (OR) = 4.25
  • renal dialysis OR = 10.90
  • pneumonia OR = 3.57

When AA-SLE were compared to the African American matched controls without SLE, the found more:

  • renal failure OR = 9.55
  • hypertensive heart and renal disease OR = 8.08,

African Americans with SLE have an increased comorbidity burden that requires close monitoring and preventative strategies. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The Microbiome and Lupus Connection Reviewed

In the current issue of the New England Journal of Medicine, Drs. James Rosenbaum and Gregg Silverstein review the pathogenesis of systemic lupus erythematosus (SLE) from the viewpoint of a dysbiolsis.

The complexity of the trillions of organisms that constitute our microbiome underscores its multiplicity of functions, including nutrient, metabolic and immune shaping functions.

SPAR Predicts ILD Progression in Systemic Sclerosis

The development and progression of interstitial lung disease in systemic sclerosis can be an ominous finding. A new analysis of two independent clinical trial cohorts shows that oxygen saturation (SpO2) < 94% after 6 minute walk time (6MWT) and the presence of arthritis predicted the development of ILD in SSc.

Low Disease Activity in Lupus Limits Damage

Patients with systemic lupus erythematosus (SLE) who were assessed as being in a low disease activity state during more than half of clinical visits had a decrease in organ damage events of approximately 50%, a retrospective study found.

Long Term Remission in SLE is Possible?

Researchers from the Toronto Lupus Clinic have described an atypical “monophasic” course in a small number (7.5%) of systemic lupus erythematosus (SLE) patients who achieved and sustained clinical remission, with most off of all medications for an average of 18 years.

Their inception SLE cohort includes patients enrolled within 18 mos of diagnosis.

Ustekinumab: A Novel Intervention in Giant Cell Arteritis

Treatment of refractory giant cell arteritis (GCA) with ustekinumab (Stelara) showed therapeutic promise as a steroid-sparing agent in a small, open-label study, Irish researchers reported.